Modality
Degrader
MOA
CD47i
Target
PD-L1
Pathway
Apoptosis
ALL
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
Aug 2021
→ Apr 2031
Phase 2Current
NCT06115099
623 pts·ALL
2025-04→2031-04·Active
NCT07293042
1,710 pts·ALL
2021-08→2025-03·Completed
2,333 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-121.1y agoPh3 Readout· ALL
2031-04-115.0y awayPh3 Readout· ALL
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Complet…
P2/3
Active
Catalysts
Ph3 Readout
2025-03-12 · 1.1y ago
ALL
Ph3 Readout
2031-04-11 · 5.0y away
ALL
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06115099 | Phase 2/3 | ALL | Active | 623 | Safety |
| NCT07293042 | Phase 2/3 | ALL | Completed | 1710 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |